Multicenter validation for a deep learning approach for enhanced urine cytological assessment and rapid bladder cancer screening

Active Grant Awarded Last action

Award ID
R01CA304989
Recipient
Awarding agency
Obligated
$746,931

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 4% complete
Place of performance
West Hollywood, CA 90048, USA

Award details come from USAspending.gov.

About this award

The National Cancer Institute within the Department of Health and Human Services National Institutes of Health awarded Cedars-Sinai Medical Center $746,931 on September 9, 2026, under Grant R01CA304989, Assistance Listing 93.394, Cancer Detection and Diagnosis Research. The grant funds a multicenter validation of AutoParisX (APX), a semi-automated screening tool that applies deep learning to digitized urine cytology slides and generates a machine learning-based atypia burden score for each patient. The work proceeds in three non-interdependent aims: collecting a large, heterogeneous set of urine cytology slides from a coalition of academic institutions contributing varied demographics, specimen preparations, and whole-slide scanners; creating the largest database of urine cytology annotations and images; and validating the APX-enabled user interface for AI-assisted review through a comprehensive reader study. Place of performance is West Hollywood, California 90048. The period of performance ends July 31, 2031. The program supports screening, early detection, and diagnostic research for cancer, including resources of human tissue for research.

Description

Abstract
Bladder cancer is the most recurrent form of cancer, making IT the most expensive cancer to treat because of the need for frequent screenings, often with cystoscopy. Urine cytology, the microscopic examination of cells from urine samples, serves as a less invasive complement to cystoscopy; however, its cost-effectiveness and impact on disease management are limited by its lower reliability, efficiency, and sensitivity. While automation has heralded a new age for PAP smear screenings over the past two decades, urine cytology has seen considerably less innovation. To address this GAP, our team developed autoparisx (APX), a semi-automated screening tool that utilizes deep learning algorithms to analyze digitized urine cytology slides. APX provides both subjective (e.g., hyperchromasia) and objective (e.g., nuclear-to-cytoplasm ratio) measurements of atypia at single-cell resolution, generating a machine learning-based atypia burden score (ABS) for each patient. ABS is predictive of malignancy and future recurrence and aligned with the paris system for reporting urinary cytology (TPS). Retrospective validation has shown an auroc of 0.9 for patient diagnoses, setting a new benchmark. However, further refinement and validation on a heterogeneous, multicenter cohort are necessary for clinical implementation. To achieve this, we have assembled a coalition of academic institutions to contribute samples from varied demographics, specimen preparations, and whole-slide scanners. This will allow US to: 1) collect a large, heterogeneous set of urine cytology slides, 2) create the largest database of urine cytology annotations/images, and 3) validate the APX-enabled user interface for AI-assisted review through a comprehensive reader study. This will be accomplished in three non-interdependent aims. In aim 1, we will leverage large-scale self-supervised learning (SSL) to create the APX foundation model-a generalizable base model built from over 625 million cellular images to reduce the data required to adapt APX to new institutions. In aim 2, we will compare methods for generating slide-level diagnoses from APX's granular cell-level information, including composite statistics (e.g., abnormal cell counts) and attention mechanisms that rank the most diagnostically relevant cells. In aim 3, we will conduct a comprehensive, multicenter reader study of traditional glass slide screening versus APX-augmented digital slide screening using a screen-washout-rescreen protocol. The reader study will leverage extensive cytopathology expertise to achieve two key objectives: a) demonstrate that APX is non-inferior to traditional glass slides in terms of diagnostic sensitivity and specificity, and B) show that APX can suggest plausible diagnoses and deliver critical cellular information in a way that expedites the review process, making IT more efficient. Usability testing will gather qualitative feedback on initial impressions, diagnostic confidence, ease of use, and ergonomics, to further enhance APX's clinical utility. These efforts will lay the groundwork for a future clinical trial to demonstrate how digital technologies can streamline high-volume bladder cancer screening and surveillance, addressing the significant burden of recurrence.

Transactions

Action Obligated Date
Amendment $0
Original award $746,931

Quick answers

Who received award R01CA304989?

R01CA304989 was awarded to Cedars-Sinai Medical Center by National Cancer Institute (National Institutes of Health) on September 9, 2026.

How much is award R01CA304989 worth?

$746,931 has been obligated on R01CA304989.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award